KSWA
REGN icon

Kathleen S. Wright Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Kathleen S. Wright Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$50.6K Hold
90
– – 0.02% 149
2025
Q2 		$47.3K Hold
90
– – 0.02% 152
2025
Q1 		$57.1K Hold
90
– – 0.02% 141
2024
Q4 		$64.1K Hold
90
– – 0.03% 142
2024
Q3 		$94.6K Sell
90
-10
-10% -$11.1K 0.04% 127
2024
Q2 		$105K Buy
+100
New +$96.9K 0.05% 123

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kathleen S. Wright Associates's REGN Position: Q3 2025 in Review

Kathleen S. Wright Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2025 at 90 shares worth $50.6K. The position accounts for 0.02% of the portfolio, ranked #149.

Kathleen S. Wright Associates first reported a position in REGN in Q2 2024 and has held it in 6 quarters since. The position peaked at $105K in Q2 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Kathleen S. Wright Associates held 90 shares of Regeneron Pharmaceuticals worth $50.6K as of Q3 2025.
  • Kathleen S. Wright Associates left its Regeneron Pharmaceuticals share count unchanged in Q3 2025.
  • Regeneron Pharmaceuticals made up 0.02% of Kathleen S. Wright Associates's portfolio in Q3 2025, its #149 holding.
  • Kathleen S. Wright Associates first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Kathleen S. Wright Associates's Regeneron Pharmaceuticals position peaked at $105K in Q2 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Kathleen S. Wright Associates's 13F filing for Q3 2025, filed 10 Oct 2025.